Abstract
Gene amplification drives oncogenesis in a large spectrum of cancers. A amount of medicines have been developed to inhibit the protein merchandise of amplified driver genes, nonetheless their medical efficacy is frequently hampered by drug resistance. Here, we introduce a therapeutic strategy for targeting cancer-connected gene amplifications by activating the DNA damage response with triplex-forming oligonucleotides (TFOs), which force the induction of apoptosis in tumors, whereas cells without amplifications job lower phases of DNA damage. Specializing in cancers driven by HER2 amplification, we obtain that TFOs targeting HER2 induce reproduction amount-dependent DNA double-strand breaks (DSBs) and spark off p53-self sustaining apoptosis in HER2-obvious cancer cells and human tumor xenografts through a mechanism that is self sustaining of HER2 mobile operate. This strategy has demonstrated in vivo efficacy a lot like that of most modern precision medicines and supplied a feasible change to strive against drug resistance in HER2-obvious breast and ovarian cancer devices. These findings provide a general strategy for targeting tumors with amplified genomic loci.
Win admission to solutions
Subscribe to Journal
Win paunchy journal obtain entry to for 1 yr
99,00 €
most attention-grabbing 8,25 € per distress
Tax calculation will be finalised all the arrangement through checkout.
Rent or Preserve article
Win time restricted or paunchy article obtain entry to on ReadCube.
from$8.99
All prices are NET prices.
Files availability
The authors tell that the solutions supporting the findings of this peer are on hand within the paper and its Supplementary Files. Source knowledge are supplied with this paper.
References
- 1.
Chen, Y. et al. Identification of druggable cancer driver genes amplified all the arrangement through TCGA datasets. PLoS ONE 9, e98293 (2014).
- 2.
Matsui, A., Ihara, T., Suda, H., Mikami, H. & Semba, Enough. Gene amplification: mechanisms and involvement in cancer. Biomol. Ideas 4, 567–582 (2013).
- 3.
Santarius, T., Shipley, J., Brewer, D., Stratton, M. R. & Cooper, C. S. A census of amplified and overexpressed human cancer genes. Nat. Rev. Most cancers 10, 59–64 (2010).
- 4.
Albertson, D. G. Gene amplification in cancer. Traits Genet. 22, 447–455 (2006).
- 5.
Ohshima, Enough. et al. Constructed-in prognosis of gene expression and reproduction amount identified doable cancer driver genes with amplification-dependent overexpression in 1,454 robust tumors. Sci. Earn. 7, 641 (2017).
- 6.
Moasser, M. M. & Krop, I. E. The evolving landscape of HER2 targeting in breast cancer. JAMA Oncol. 1, 1154–1161 (2015).
- 7.
Slamon, D. J. et al. Reports of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707–712 (1989).
- 8.
Baselga, J., Albanell, J., Molina, M. A. & Arribas, J. Mechanism of action of trastuzumab and scientific update. Semin. Oncol. 28, 4–11 (2001).
- 9.
Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-obvious metastatic breast cancer. N. Engl. J. Med. 372, 724–734 (2015).
- 10.
Wilks, S. T. Likely of overcoming resistance to HER2-focused therapies through the PI3K/Akt/mTOR pathway. Breast 24, 548–555 (2015).
- 11.
Petty, R. D. et al. Gefitinib and EGFR gene reproduction amount aberrations in esophageal cancer. J. Clin. Oncol. 35, 2279–2287 (2017).
- 12.
Pao, W. et al. Received resistance of lung adenocarcinomas to gefitinib or erlotinib is expounded with a second mutation within the EGFR kinase area. PLoS Med. 2, e73 (2005).
- 13.
Ricciardi, A. S., McNeer, N. A., Anandalingam, Enough. Enough., Saltzman, W. M. & Glazer, P. M. Centered genome modification through triple helix formation. Techniques Mol. Biol. 1176, 89–106 (2014).
- 14.
Gaddis, S. S. et al. A internet-based entirely search engine for triplex-forming oligonucleotide target sequences. Oligonucleotides 16, 196–201 (2006).
- 15.
Ebbinghaus, S. W. et al. Triplex formation inhibits HER-2/neu transcription in vitro. J. Clin. Make investments. 92, 2433–2439 (1993).
- 16.
Kaushik Tiwari, M. & Rogers, F. A. XPD-dependent activation of apoptosis in accordance with triplex-brought on DNA damage. Nucleic Acids Res. 41, 8979–8994 (2013).
- 17.
Kaushik Tiwari, M., Adaku, N., Peart, N. & Rogers, F. A. Triplex structures induce DNA double strand breaks through replication fork collapse in NER deficient cells. Nucleic Acids Res. 44, 7742–7754 (2016).
- 18.
Rogers, F. A., Vasquez, Enough. M., Egholm, M. & Glazer, P. M. Location-directed recombination through bifunctional PNA–DNA conjugates. Proc. Natl Acad. Sci. USA 99, 16695–16700 (2002).
- 19.
Wang, G., Seidman, M. M. & Glazer, P. M. Mutagenesis in mammalian cells attributable to triple helix formation and transcription-coupled restore. Science 271, 802–805 (1996).
- 20.
Szollosi, J., Balazs, M., Feuerstein, B. G., Benz, C. C. & Waldman, F. M. ERBB-2 (HER2/neu) gene reproduction amount, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Most cancers Res. 55, 5400–5407 (1995).
- 21.
Vergote, I. et al. Neoadjuvant chemotherapy or necessary surgical treatment in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943–953 (2010).
- 22.
Jenjaroenpun, P. & Kuznetsov, V. A. TTS mapping: integrative WEB tool for prognosis of triplex formation target DNA sequences, G-quadruplets and non-protein coding regulatory DNA ingredients within the human genome. BMC Genomics 10, S9 (2009).
- 23.
Cook, P. J. et al. Tyrosine dephosphorylation of H2AX modulates apoptosis and survival choices. Nature 458, 591–596 (2009).
- 24.
zum Buschenfelde, C. M., Hermann, C., Schmidt, B., Peschel, C. & Bernhard, H. Antihuman epidermal yell ingredient receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic shriek of sophistication I-restricted HER2-command T lymphocytes against HER2-overexpressing tumor cells. Most cancers Res. 62, 2244–2247 (2002).
- 25.
Cuello, M. et al. Down-laws of the erbB-2 receptor by trastuzumab (Herceptin) enhances tumor necrosis ingredient-connected apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell traces that overexpress erbB-2. Most cancers Res. 61, 4892–4900 (2001).
- 26.
Deng, Y. et al. The fabricate of hyperbranched polyglycerol coatings on drug shipping the utilization of degradable polymer nanoparticles. Biomaterials 35, 6595–6602 (2014).
- 27.
Bindra, R. S. & Glazer, P. M. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 26, 2048–2057 (2007).
- 28.
Balashanmugam, M. V. et al. Preparation and characterization of unique PBAE/PLGA polymer blend microparticles for DNA vaccine shipping. ScientificWorldJournal 2014, 385135 (2014).
- 29.
Web thunder positioning, Y. E. et al. Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials 201, 87–98 (2019).
- 30.
Oeck, S. et al. The Focinator v2-0—graphical interface, four channels, colocalization prognosis and cell segment identification. Radiat. Res. 188, 114–120 (2017).
- 31.
Oeck, S., Malewicz, N. M., Hurst, S., Rudner, J. & Jendrossek, V. The Focinator—a unique commence-source tool for excessive-throughput foci evaluate of DNA damage. Radiat. Oncol. 10, 163 (2015).
- 32.
Mandl, H. Enough. et al. Optimizing biodegradable nanoparticle dimension for tissue-command shipping. J. Preserve an eye fixed on. Release 314, 92–101 (2019).
Acknowledgements
This work became once supported by grants from the Nationwide Most cancers Institute (NCI) of the Nationwide Institutes of Correctly being (NIH) R21CA185192 to F.A.R., the Breast Most cancers Alliance Distinctive Project Grant to F.A.R., Nationwide Institute of Total Clinical Sciences R01GM126211 to F.A.R. and NIH R01CA149128 to W.M.S. E.Q. became once supported by coaching grants T32GM07205 and 5T32GM007223-43.
Ethics declarations
Competing pursuits
Yale College has filed patent purposes connected to this work (inventor F.A.R.).
Further knowledge
Watch overview knowledge Nature Biotechnology thanks Carlo V. Catapano and the other, nameless, reviewer(s) for their contribution to the peer overview of this work.
Publisher’s present Springer Nature remains honest in regards to jurisdictional claims in revealed maps and institutional affiliations.
Prolonged knowledge
Prolonged Files Fig. 1 Experiments Supporting Essential Fig. 2.
(a) Representative photos of honest comet assays performed 24?h after HER2-205 medication in MCF7 and BT474 cells (scale bars, 200?m). (b) Quantification of cells with elevated than 5 ?H2AX and/or 53BP1 foci per nuclei in BT474 cells treated with HER2-205 or MIX24 (imply ± SD; two-arrangement ANOVA with Tukey take a look at put up-hoc; P?c) Triplex formation induces apoptosis in HER2-obvious breast cancer cell traces as measured by Western blot prognosis of cleaved PARP (n?=?3 self sustaining experiments). (d) Detection of HER2 copies in interphase nuclei by dual color FISH with HER2 probe (purple) and chromosome 17 probe (inexperienced), scale bars, 2.5 ?m. (e) Immunofluorescence of ?H2AX in PE01 ovarian cancer cells 24?h put up-medication with HER2-205 or MIX24 (scale bars, 5 ?m). (f) Representative immunofluorescence photos of ?H2AX foci in SKOV3 ovarian cancer cells 24?h following medication with HER2-205 or MIX24 (scale bars, 2.5 ?m). (g) Frequency of PE01 and SKOV3 cells obvious for ?H2AX following 24?h medication (imply ± SD; two-arrangement ANOVA with Tukey take a look at put up-hoc; P?h) Quantification of triplex-brought on DNA double strand breaks the utilization of the honest comet assay as measured by tail moment (imply ± SEM; two-arrangement ANOVA with Tukey take a look at put up-hoc, P?i) Monolayer yell assay demonstrates a lower in cell survival in PE01 and SKOV3 cells treated with HER2-205 72?h after medication. (j) Western blot prognosis of activation of apoptosis as measured by cleaved PARP in ovarian cancer cells following TFO medication (n?=?3 self sustaining experiments).
Prolonged Files Fig. 2 Experiments Supporting Essential Fig. 5.
(a) ChIP prognosis of ?H2AX in BT474 cells detected elevated DNA damage at the focused HER2 gene following HER2-5922 medication. Files are presented as imply ± SEM and analyzed by two-arrangement ANOVA with Tukey take a look at put up-hoc, P?b) Quantification of phosphorylated ATM by drift cytometry following medication with HER2-205. Files are presented as imply ± SEM and analyzed by one-arrangement ANOVA with Tukey take a look at put up-hoc, *P?c) Evaluation of HER2 gene expression by RT-PCR 12?h put up-medication with HER2-focused TFOs (imply ± SD; two-ANOVA with Tukey take a look at put up-hoc; ns, no longer principal; n?=?3 self sustaining experiments). (d) Quantification of triplex-brought on DNA double strand breaks the utilization of the honest comet assay as measured by tail moment 12?h put up TFO medication (imply ± SEM; one-ANOVA with Tukey take a look at put up-hoc; P?e) Western blot prognosis of activation of apoptosis as measured by cleaved PARP and pH2AX Y142 12?h following TFO medication (book immunoblots, n?=?2 self sustaining experiments). Western blot prognosis of the phosphorylation position of HER family receptors (f) HER3, (g) HER4, and (h) EGFR (HER1) in more than one breast cancer cell traces following HER2-205 medication (book immunoblots, n?=?2). (i) Evaluation of HER2 gene expression by RT-PCR 12?h put up-medication with HER2-focused TFOs (imply ± SEM; one-arrangement ANOVA with Tukey take a look at put up-hoc; ns, no longer principal; n?=?3 self sustaining experiments). (j) Evaluation of HER2 gene expression by RT-PCR 20?h following pretreatment with the transcription inhibitor, ?-amanitin (imply ± SD; one-arrangement ANOVA with Tukey take a look at put up-hoc; P?
Prolonged Files Fig. 3 Biodistribution of nanoparticle formulations.
Comparison of PLGA and PLA-HPG NPs in vivo. (a) Uptake of DiD-loaded NPs, PLGA/DCM, PLGA/EtOAc and PLA-HPG, 12?h after systemic administration through retro-orbital injection. Tumor cryosections visualize DAPI (blue) and DiD (purple) (scale bars, 50 ?m; n?=?2 tumors). (b) Biodistribution of DiD-loaded PLA-HPG NPs 12?h after systemic administration. DiD fluorescence in isolated organs after retro-orbital injection with DiD encapsulated NPs (2?mg). Cryosections visualize DAPI (blue) and DiD (purple) (scale bars, 50 ?m; n?=?2 animals).
Prolonged Files Fig. 4 Experiments Supporting Essential Fig. 6.
Biodistribution of TAMRA-HER2-205 encapsulated PLA-HPG nanoparticles (NPs). (a) Representative confocal photos of tissue sections 12?hours put up intravenous administration through retro-orbital injection of a 2?mg dose of NPs (scale bars, 50 ?m). (b) Representative confocal photos of TAMRA-HER2-205 biodistribution in tissues 24?hours put up medication (scale bars, 50 ?m). (c) TAMRA fluorescence became once quantified at both 12 and 24?hours after dosing (2?mg of NPs) and TFO uptake in each tissue is reported as imply fluorescence depth (MFI) (imply ± SEM, n?=?2 mice). Statistical significance became once calculated by one-arrangement ANOVA and Kruskal-Wallis take a look at P?d) Evaluation of TAMRA-HER2-205 biodistribution 12?h put up medication. Fluorescence depth noticed in each tissue is reported as a share of the mixed total fluorescence depth detected in spleen, kidney, liver and tumor (tumor knowledge is shown and quantified in Fig. 6a,b). Entire house of the pie chart denotes the sum of completely the fluorescence within the four organs, representing the overall TFO uptake by these organs, and each chop provides the relative HER2-205 uptake for each organ. (e) Evaluation of TAMRA-HER2-205 biodistribution 24?h put up systemic administration. Fluorescence depth noticed in each tissue is reported as a share of the mixed total fluorescence depth detected in spleen, kidney, liver and tumor (tumor knowledge is shown and quantified in Fig. 6a,b). Entire house of the pie chart denotes the sum of completely the fluorescence within the four organs, representing the overall TFO uptake by these organs, and each chop provides the relative HER2-205 uptake for each organ.
Prolonged Files Fig. 5 Experiments Supporting Essential Fig. 6.
(a) Nanoparticle Characterization. Nanoparticle diameter as measured by dynamic gentle scattering. Nanoparticle ground label measured by zeta doable. Nanoparticle loading of TFOs measured by extraction and prognosis. All knowledge is plotted as imply ± SEM, n?=?3 experiments. (b) Representative photos of confocal microscopy of ?H2AX immunofluorescence in tumors 24?h put up-medication with HER2-205 PLA-HPG NPs and quantification of ?H2AX foci is reported as imply fluorescence depth (MFI) (imply ± SEM; Kolmogorov-Smirnov take a look at; P?c) Representative photos of confocal microscopy of cleaved caspase 3 immunofluorescence in tumors 12?h put up-medication with HER2-205 PLA-HPG NPs and quantification of activated caspase 3 is reported as imply fluorescence depth (imply ± SEM; Kolmogorov-Smirnov take a look at; P?d) HER2 immunofluorescence prognosis of BT474 tumor sections from mice 12?h and 24?h after medication with a single dose of HER2-205 PLA-HPG NPs (2?mg). Files represented as imply ± SEM and analyzed by one-arrangement ANOVA Kruskal-Wallis take a look at (n?=?4 tumors/time level; ns, no longer principal). Scale bar, 10?m. (e) Confocal microscopy photos of tumor sections analyzed by immunofluorescence 12?h and 24?h following a single dose of TAMRA-HER2-205 PLA-HPG NPs (scale bars, 10?m).
Prolonged Files Fig. 6 ESI-MS and HPLC characterization of TFOs.
(a) Analytical ESI-MS spectrum of HER2-205. (b) Analytical reverse-phased HPLC of HER2-205. (c) Analytical ESI-MS spectrum of HER2-5922. (d) Analytical reverse-phased HPLC of HER2-5922.
Prolonged Files Fig. 7 Circulation cytometry profiles.
A single cell homogeneous population became once utilized for FCS/SSC gating of the starting up cell population. (a) Circulation cytometry profiles of BT474 cells stained for Annexin V-FITC/PI to measure apoptotic cells. Cells were harvested 24?h after medication. Lower lawful quadrant represents the mixed share of early and leisurely apoptotic cells. (b) Circulation cytometry profiles of BT474 cells stained for pATM. Cells were harvested 24?h after medication. The box indicates the gate for excessive phases of pATM and numbers signify share of cells with excessive phases of pATM.
Supplementary knowledge
About this article
Cite this article
Kaushik Tiwari, M., Colon-Rios, D.A., Tumu, H.C.R. et al. Narrate targeting of amplified gene loci for proapoptotic anticancer remedy.
Nat Biotechnol (2021). https://doi.org/10.1038/s41587-021-01057-5
-
Bought:
-
Authorized:
-
Published:
